By Beth Treffeisen January 12, 2026

Tessera Therapeutics, a high-profile Somerville biotech developing next-generation gene-writing technology, is cutting about 35% of its workforce as it shifts its focus to a new partnership with Regeneron.

The company notified the state on Wednesday that it will lay off 90 employees, including 82 Massachusetts residents, beginning March 8. Tessera said the job cuts are permanent but will include severance, and no facilities will close.

After this round of layoffs, the company will have roughly 160 employees, according to a company spokesperson.

Read Full Story